Literature DB >> 15112354

Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer.

Guo-Xiong Zhou1, Jie-Fei Huang, Zhao-Shen Li, Guo-Ming Xu, Feng Liu, Hong Zhang.   

Abstract

AIM: To study the value of monitoring K-ras point mutation at codon 12 and telomerase activity in exfoliated cells obtained from pancreatic duct brushings during endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of pancreatic cancer.
METHODS: Exfoliated cells obtained from pancreatic duct brushings during ERCP were examined in 27 patients: 23 with pancreatic cancers, 4 with chronic pancreatitis. K-ras point mutation was detected with the polymerase chain reaction and restriction fragment-length polymorphism (PCR-RFLP). Telomerase activity was detected by PCR and telomeric repeat amplification protocol assay (PCR-TRAP-ELISA).
RESULTS: The telomerase activities in 27 patients were measured in 21 exfoliated cell samples obtained from pancreatic duct brushings. D450 value of telomerase activities in pancreatic cancer and chronic pancreatitis were 0.446+/-0.27 and 0.041+/-0.0111, respectively. Seventy-seven point eight percent (14/18) of patients with pancreatic cancer and none of the patients with chronic pancreatitis showed telomerase activity in cells collected from pancreatic duct brushings when cutoff value of telomerase activity was set at 2.0. The K-ras gene mutation rate (72.2%) in pancreatic cancer was higher than that in chronic pancreatitis (33.3%) (P<0.05). In considering of both telomerase activities and K-ras point mutation, the total positive rate was 83.3%(15/18), and the specificity was 100%.
CONCLUSION: Changes of telomerase activities and K-ras point mutation at codon 12 may be an early event of malignant progression in pancreatic cancer. Detection of telomerase activity and K-ras point mutation at codon 12 may be complementary to each other, and is useful in diagnosis of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15112354      PMCID: PMC4622778          DOI: 10.3748/wjg.v10.i9.1337

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma.

Authors:  A Ha; H Watanabe; Y Yamaguchi; K Ohtsubo; Y Wang; Y Motoo; T Okai; T Wakabayahi; N Sawabu
Journal:  Pancreas       Date:  2001-11       Impact factor: 3.327

Review 2.  Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas.

Authors:  W Kimura; B Zhao; N Futakawa; T Muto; M Makuuchi
Journal:  Hepatogastroenterology       Date:  1999 Jan-Feb

3.  K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.

Authors:  A Castells; P Puig; J Móra; J Boadas; L Boix; E Urgell; M Solé; G Capellà; F Lluís; L Fernández-Cruz; S Navarro; A Farré
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

4.  Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas.

Authors:  Massimo Raimondo; Issei Tachibana; Raul Urrutia; Lawrence J Burgart; Eugene P DiMagno
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

5.  Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer.

Authors:  N Futakawa; W Kimura; S Yamagata; B Zhao; H Ilsoo; T Inoue; N Sata; Y Kawaguchi; Y Kubota; T Muto
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

6.  A prospective study of K-ras mutations in the plasma of pancreatic cancer patients.

Authors:  H E Mulcahy; J Lyautey; C Lederrey; X qi Chen; P Anker; E M Alstead; A Ballinger; M J Farthing; M Stroun
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

7.  Semi-quantitative analysis of telomerase in pancreatic ductal adenocarcinoma.

Authors:  K Mizumoto; N Suehara; T Muta; S Kitajima; N Hamasaki; Y Tominaga; H Shimura; M Tanaka
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

8.  Early detection of pancreatic cancer in patients with chronic pancreatitis: diagnostic utility of a K-ras point mutation in the pancreatic juice.

Authors:  P E Queneau; G L Adessi; P Thibault; D Cléau; B Heyd; G Mantion; P Carayon
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

9.  Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas.

Authors:  Koji Yoshizawa; Hideo Nagai; Shinji Sakurai; Mitsugu Hironaka; Shojiroh Morinaga; Ken Saitoh; Masashi Fukayama
Journal:  Virchows Arch       Date:  2002-10-12       Impact factor: 4.064

10.  Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease.

Authors:  M Tada; M Ohashi; Y Shiratori; T Okudaira; Y Komatsu; T Kawabe; H Yoshida; R Machinami; K Kishi; M Omata
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

View more
  2 in total

Review 1.  Diagnosis and management of relapsing pancreatitis associated with cystic neoplasms of the pancreas.

Authors:  William-R Brugge
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

2.  Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.

Authors:  C Salek; L Benesova; M Zavoral; V Nosek; L Kasperova; M Ryska; R Strnad; E Traboulsi; M Minarik
Journal:  World J Gastroenterol       Date:  2007-07-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.